Integrated Financials for the Financial Year Ended 31st March 2025
AMRUTANJAN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Amrutanjan Health Care reported FY25 revenue from operations of ₹451.82 crore, up about 7.3% from ₹421.23 crore in FY24. Profit after tax grew roughly 13% to ₹50.83 crore from ₹44.97 crore, translating to EPS of ₹17.58 versus ₹15.50. Q4 FY25 revenue was ₹135.41 crore (up ~6.6% YoY) with Q4 PAT at ₹15.18 crore (up ~11% YoY). Operating cash flow improved sharply to ₹50.90 crore from ₹27.91 crore, and cash on hand nearly tripled to ₹10.16 crore. The board has recommended a final dividend of ₹2.60 per share, on top of an interim ₹1.00 already paid during the year. The auditor (B S R & Co. LLP) issued an unmodified opinion, and the current Company Secretary retires on 31 May 2025 with a successor appointed from 1 June 2025.
Steady mid-single-digit revenue growth and double-digit profit growth, supported by strong operating cash generation, is a constructive signal for shareholders. The total dividend of ₹3.60 per share offers a reasonable yield, while higher capex (₹35.55 crore vs ₹6.72 crore) and expansion of capital work-in-progress suggest the company is investing in future capacity, which could weigh on near-term margins if revenue growth does not accelerate.